Oral Arsenic-based Regimen for Relapsed/Refractory Mantle Cell Lymphoma

Share this content:

the Cancer Therapy Advisor take:

Typically, patients with mantle cell lymphoma (MCL), especially those with relapsed or refractory disease, experience poor outcomes. An oral arsenic-based regimen, however, may prove beneficial in this patient population, according to a study published in Annals of Oncology.


In the study, researchers administered a continuous oral regimen comprised of oral arsenic trioxide (oral-As203), chlorambucil and ascorbic acid to 39 patients, 34 of whom were men and five of whom were women, aged 41 to 82 years of age with relapsed/refractory MCL. Patients were ineligible for high-dose chemotherapy and had previously received one to five prior regimens.


Data indicated an overall response rate of 49%, with 28% experiencing complete response and 21% experiencing partial response. Eleven patients, including eight complete responders and three partial responders, maintained response after a median of 24 months. The researchers noted increased lactate dehydrogenase and an unfavorable MCL international prognostic index were independent prognostic factors for response.


After a median follow-up of 21 months, progression-free survival (PFS) was 16 months and overall survival (OS) was 38 months, according to the researchers. Female gender and an Eastern Cooperative Oncology Group performance score of 2 were deemed independent prognostic factors for PFS, while female gender, an ECOG performance score of 2, non-response, and disease progression after initial response were independently linked to OS.


The researchers found only grade 1 or 2 toxicities, 56% of which were hematologic and 8% of which were hepatic, leading them to conclude that this regimen may be appropriate for some patients with MCL.

Potential Therapy for Rare, Drug-resistant GISTs
Oral Arsenic-based Regimen for Relapsed/Refractory Mantle Cell Lymphoma

Mantle cell lymphoma (MCL) is aggressive, and relapsed/refractory disease has poor outcomes, but a novel approach involving an oral arsenic-based regimen may help improve treatment.

To evaluate the potential of this regimen, researchers conducted a study involving 39 patients with relapsed/refractory MCL, ineligible for high-dose chemotherapy and had received two prior regimens, were treated with a continuous oral regimen, comprising oral arsenic trioxide, chlorambucil and ascorbic acid.

READ FULL ARTICLE From Annals of Oncology

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs